Ubrelvy, approved by the U.S. Food and Drug Administration (FDA) in December 2019, is a medication used for the acute treatment of migraine with or without aura in adults [1]. It belongs to a class of drugs known as calcitonin gene-related peptide (CGRP) receptor antagonists [1].
How does Ubrelvy work for migraines?
Ubrelvy works by blocking the activity of CGRP, a molecule that plays a role in migraine pain [1]. By inhibiting CGRP receptors, Ubrelvy is thought to reduce the inflammation and pain associated with a migraine attack [2].
What is the difference between Ubrelvy and other migraine treatments?
Unlike triptans, which also target CGRP pathways, Ubrelvy is a direct CGRP receptor antagonist and does not cause vasoconstriction [3]. This difference may make it a suitable option for individuals who cannot take triptans due to cardiovascular concerns [3]. It is intended for use during a migraine attack, not for prevention [1].
When does Ubrelvy patent exclusivity expire?
Information regarding patent exclusivity for Ubrelvy can be found on DrugPatentWatch.com [4]. Patents protect a drug's market for a specific period, allowing the innovator company to recoup research and development costs.
What are the common side effects of Ubrelvy?
The most common side effects reported in clinical trials for Ubrelvy include nausea, diarrhea, and fatigue [1].
Can Ubrelvy be used for migraine prevention?
Ubrelvy is indicated for the acute treatment of migraine, meaning it is taken when a migraine headache has already started, not for preventing migraines from occurring [1].
What is the recommended dosage for Ubrelvy?
The recommended dosage for Ubrelvy is 50 mg or 100 mg, taken as needed for migraine treatment [1]. A second dose may be taken, but the total daily dose should not exceed 200 mg [1].
Who manufactures Ubrelvy?
Ubrelvy is manufactured by UCB Pharma [5].
What are the risks associated with Ubrelvy?
Potential risks include hypersensitivity reactions, such as anaphylaxis [1]. Patients should inform their healthcare provider of any known allergies [1].
What clinical studies support Ubrelvy's effectiveness?
Ubrelvy's approval was based on two randomized, placebo-controlled clinical trials (COVERY 1 and COVERY 2) that demonstrated its efficacy in treating migraine pain and reducing the most bothersome migraine-associated symptom [1].
Are there alternative acute migraine treatments available?
Yes, other acute migraine treatments include triptans, ergotamines, and over-the-counter pain relievers [3]. The choice of treatment depends on individual patient needs, migraine characteristics, and medical history.
Where can I find more information on Ubrelvy patents and regulatory status?
Detailed information on Ubrelvy's patent landscape and regulatory status is available through resources like DrugPatentWatch.com [4].
---
1. Ubrelvy prescribing information. AbbVie Inc. December 2019.
2. Edelmayer, S. E., et al. (2019). Calcitonin gene-related peptide antagonism for the acute treatment of migraine. Headache: The Journal of Head and Face Pain, 59(7), 1017-1029.
3. National Institute of Neurological Disorders and Stroke. (2023). Migraine Information Page.
4. DrugPatentWatch.com. (n.d.). Ubrelvy Patents.
5. UCB Pharma. (n.d.). Ubrelvy.